Impact of American Urological Association risk category on outcomes of intravesical BCG vs gemcitabine/docetaxel in high‐grade Ta non‐muscle‐invasive bladder cancer
Treatment with Gem/Doce is a well-tolerated, effective alternative to BCG for HG Ta NMIBC. In this subset, AUA risk stratification (IR vs HR) was not significantly associated with recurrence outcomes, warranting prospective validation.
Authors
- Sarah L. Mott (ORCID: https://orcid.org/0000-0001-9381-2080)
- Ian M. McElree (ORCID: https://orcid.org/0000-0001-9991-4301)
- Michael A O'Donnell
- Mohamad Abou Chakra
Institutions
- University of Iowa (US)
- University of Iowa Health Care (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- British Journal of Urology
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1111/bju.70149
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00